title: Primary non-Hodgkin's lymphoma of the bone: a single institution experience.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India 400012.
authors.forename: C
authors.initials: C
authors.lastname: Deshmukh
authors.forename: A
authors.initials: A
authors.lastname: Bakshi
authors.forename: P
authors.initials: P
authors.lastname: Parikh
authors.forename: R
authors.initials: R
authors.lastname: Nair
authors.forename: V
authors.initials: V
authors.lastname: Pai
authors.forename: S
authors.initials: S
authors.lastname: Gupta
authors.forename: A
authors.initials: A
authors.lastname: Shaikh
authors.forename: M
authors.initials: M
authors.lastname: Muckaden
authors.forename: K
authors.initials: K
authors.lastname: Naresh
authors.forename: T
authors.initials: T
authors.lastname: Saikia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012074:Remission Induction; D016019:Survival Analysis; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone